Declan Daly is the Chief Operating Officer & Chief Financial Officer of Fibrocell, Inc, an aesthetic and therapeutic development stage biotechnology company focused on developing and commercializing novel skin and tissue rejuvenation products utilizing the Company’s proprietary Fibrocell Therapy technology platform. Fibrocell Therapy is a proprietary autologous cellular technology platform with far-ranging potential applications in both aesthetic and therapeutic applications. Based in Exton, Pennsylvania, Fibrocell Therapy represents a true cellular platform technology with applications that extend beyond the dermatology field. Dublin born Daly is a graduate of Trinity College and University College Dublin and a former employee of INAMED Corporation, BDO Simpson Xavier, and PricewaterhouseCoopers. Daly’s immediate plan is to obtain FDA approval for Fibrocell Science’s lead product, which is currently in late Phase III.  The plan is to then develop the Fibrocell extensive platform. Daly is married with three children.
 

Return to Life Science 50